Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SELP | P16109 | 2/20 | 0.73 |
| ▸ | SELL | P14151 | 1/20 | 0.73 |
| ▸ | SIGLEC7 | Q9Y286 | 6/20 | 0.62 |
| ▸ | SELE | P16581 | 5/20 | 0.61 |
| ▸ | MAG | P20916 | 6/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29372449 | 1.00 | SELP (0.73) | SELPSELLSIGLEC7SELEMAG | |
| SCHEMBL13195877 | 1.00 | SELP (0.73) | SELPSELLSIGLEC7SELEMAG | |
| SCHEMBL29405702 | 1.00 | SELP (0.73) | SELPSELLSIGLEC7SELEMAG | |
| SCHEMBL13978771 | 1.00 | SELP (0.73) | SELPSELLSIGLEC7SELEMAG | |
| SCHEMBL29389517 | 1.00 | SELP (0.73) | SELPSELLSIGLEC7SELEMAG | |
| SCHEMBL29448496 | 1.00 | SELP (0.73) | SELPSELLSIGLEC7SELEMAG | |
| SCHEMBL29407985 | 0.99 | SELP (0.71) | SELPSELLSIGLEC7SELEMAG | |
| SCHEMBL29466129 | 0.98 | SELP (0.70) | SELPSELLSIGLEC7SELEMAG | |
| SCHEMBL29466139 | 0.98 | SELP (0.70) | SELPSELLSIGLEC7SELEMAG | |
| SCHEMBL31010809 | 0.96 | SELP (0.71) | SELPSELLSIGLEC7SELEMAG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12552876-B2 | Anti-fucosyl-GM1 antibodies | SCANCELL LIMITED (GB) | 2026-02-17 | — | — | US | disclosed |
| EP-4025612-B1 | ANTI-FUCOSYL-GM1 ANTIBODIES | SCANCELL LTD (GB) | 2025-10-29 | — | — | EP | disclosed |
| US-20220267466-A1 | ANTI-FUCOSYL-GM1 ANTIBODIES | SCANCELL LIMITED (GB) | 2022-08-25 | — | — | US | disclosed |
| CN-108137695-B | Sialylated diluisia a expressed on glycoproteins other than glycolipids as a functional cancer target and antibodies thereto | 斯坎塞尔有限公司 | 2022-03-29 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12552876-B2 | Anti-fucosyl-GM1 antibodies | FUCA1, FUCA2, SIGLEC7 | SELP 1683/4885SELL 536/4885SIGLEC7 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.